Helping You Build Wealth With Honest Research
Since 1996. Try Now

MEMBER'S LOGIN

MEMBER'S LOGINX

     
Invalid Username / Password
   
     
   
     
 
Invalid Captcha
   
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

Indian share markets remain buoyant
Wed, 17 Jul 11:30 am

Indian share markets have remained buoyant in the last two hours of trade. Power and consumer durables are leading the pack of winners while metals and banking are facing the maximum selling pressures.

The BSE-Sensex is up by 100 points and NSE-Nifty is up by 24 points. BSE Mid Cap and BSE Small Cap indices are up by 0.6% and 0.7% respectively. The rupee is trading at 59.34 to the US dollar.

Mid and small cap IT shares are trading on a mixed note with Zylog Systems and Micro Tech leading the gains while Ramco Systems and Datamatics Global are facing the maximum selling pressures. NIIT Technologies has reported its 1QFY14 results. Consolidated 'net sales' have grown by 0.9% sequentially while operating margin has declined by 2% QoQ. The huge rise in 'other income' by 1371% QoQ has led the 'profit before tax' growth by 18% QoQ. However, 'net profit' has declined by 6% QoQ as the effective tax rate has increased from 18.2% at the end of 4QFY13 to 35.2% at the end of 1QFY14. The net profit margin has decreased by 0.7% QoQ and has stood at 9.8% .The Company has secured fresh orders of US$ 145 m. This has led to an order book of US$ 263 m executable over next 12 months. NIIT Technologies share is trading up by 1.44%.

Indian Pharma shares are trading on a mixed note with Dishman Pharma and Natco Pharma leading the gains while Indoco Remedies and Aurobindo Pharma are leading the losses. According to a leading financial news medium, Cipla has completed the acquisition of 100% of the issued shares of Medpro. The listing of the shares of Medpro on the Johannesburg Stock Exchange has been terminated from the commencement of business hours on July 16, 2013. Cipla has offered US$ 488 m to acquire the stake in Medpro.

Earlier, Cipla received an approval from the Takeover Regulation Panel for its proposal to takeover Medpro in South Africa.

Medpro focuses on the development of new formulations and has a wide range of pharmaceutical products. It offers prescription drugs, bulk drugs, animal products and pesticides. It also offers a wide range of food and beverages, baked foods, oral hygiene products, detergents, room fresheners and personal care products. Cipla's share is trading down by 0.4%.

For information on how to pick stocks that have the potential to deliver big returns, download our special report now!

View all commentaries | Archives

Read the latest Market Commentary


Equitymaster requests your view! Post a comment on "Indian share markets remain buoyant". Click here!

  
ABOUT EQUITYMASTER

Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.

PREMIUM PRODUCTS
QUICK LINKS
POPULAR TOPICS
TRENDING TOPICS
FREE NEWSLETTERS
EQUITYMASTER SUPPORTS
  • HelpYourNGO
  • You Tube
  • Linkedin
  • Twitter
  • Telegram
  • Google Play

Copyright © Equitymaster Agora Research Private Limited.

Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap

Phone +91-9136015013

Equitymaster Agora Research Private Limited (Research Analyst)
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.

103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Email: info@equitymaster.com. Website: www.equitymaster.com.
CIN:U74999MH2007PTC175407

Name of the Compliance & Grievance Officer: Ms Sonal Ramachandran
Telephone: +91-22-61434003 | Email: compliance@equitymaster.com

LEGAL DISCLAIMER:
Investment in securities market are subject to market risks. Read all the related documents carefully before investing.
Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.

Equitymaster Agora Research Private Limited (Research Analyst) bearing Registration No. INH000000537 (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.